Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

December 31, 2011

Conditions
Lung CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

Carboplatin

Intravenous (IV) on Day 1 of each 21-day cycle, as per dose escalation schedule (dose levels 1 and 2: dose levels 3 and 4). Number of cycles: 6 maximum.

DRUG

Etoposide

80mg/m2, Intravenous on Days 1, 2, 3 of a 21-day cycle (all dose levels). Number of cycles: 6 maximum.

DRUG

RAD001

Orally on Days 1-21 of a 21-day cycle, as per dose escalation schedule (dose level 1: 2.5 mg, dose level 2: 5 mg, dose level 3: 5.0 mg, and dose level 4: 10.0 mg). Number of cycles: unlimited (drug taken from Day 1 until progression of disease or unacceptable toxicity).

Trial Locations (1)

95817

University of California Davis Cancer Center, Sacramento

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of California, Davis

OTHER

NCT00807755 - Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors | Biotech Hunter | Biotech Hunter